vs
Side-by-side financial comparison of CaliberCos Inc. (CWD) and TScan Therapeutics, Inc. (TCRX). Click either name above to swap in a different company.
CaliberCos Inc. is the larger business by last-quarter revenue ($4.1M vs $2.6M, roughly 1.6× TScan Therapeutics, Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -895.1%, a 706.8% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs -52.5%). Over the past eight quarters, TScan Therapeutics, Inc.'s revenue compounded faster (-9.7% CAGR vs -57.6%).
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.
CWD vs TCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $2.6M |
| Net Profit | $-7.7M | $-23.0M |
| Gross Margin | — | — |
| Operating Margin | -196.6% | -929.4% |
| Net Margin | -188.3% | -895.1% |
| Revenue YoY | -52.5% | 286.0% |
| Net Profit YoY | 32.2% | 35.8% |
| EPS (diluted) | $1.95 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1M | $2.6M | ||
| Q3 25 | $3.6M | $2.5M | ||
| Q2 25 | $5.1M | $3.1M | ||
| Q1 25 | $7.3M | $2.2M | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $11.3M | $1.0M | ||
| Q2 24 | $8.2M | — | ||
| Q1 24 | $23.0M | — |
| Q4 25 | $-7.7M | $-23.0M | ||
| Q3 25 | $-4.4M | $-35.7M | ||
| Q2 25 | $-5.3M | $-37.0M | ||
| Q1 25 | $-4.4M | $-34.1M | ||
| Q4 24 | $-11.4M | — | ||
| Q3 24 | $146.0K | $-29.9M | ||
| Q2 24 | $-4.7M | — | ||
| Q1 24 | $-3.8M | — |
| Q4 25 | -196.6% | -929.4% | ||
| Q3 25 | -129.6% | -1475.6% | ||
| Q2 25 | -112.4% | -1256.6% | ||
| Q1 25 | -62.7% | -1669.7% | ||
| Q4 24 | -236.8% | — | ||
| Q3 24 | 0.0% | -3109.8% | ||
| Q2 24 | -65.0% | — | ||
| Q1 24 | -22.9% | — |
| Q4 25 | -188.3% | -895.1% | ||
| Q3 25 | -120.2% | -1422.1% | ||
| Q2 25 | -104.5% | -1201.3% | ||
| Q1 25 | -60.7% | -1571.9% | ||
| Q4 24 | -247.6% | — | ||
| Q3 24 | 1.3% | -2849.1% | ||
| Q2 24 | -57.8% | — | ||
| Q1 24 | -16.6% | — |
| Q4 25 | $1.95 | $-0.18 | ||
| Q3 25 | $-1.65 | $-0.28 | ||
| Q2 25 | $-4.15 | $-0.28 | ||
| Q1 25 | $-3.85 | $-0.26 | ||
| Q4 24 | $-10.15 | — | ||
| Q3 24 | $0.12 | $-0.25 | ||
| Q2 24 | $-4.34 | — | ||
| Q1 24 | $-3.53 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.9M | $152.4M |
| Total DebtLower is stronger | — | $32.5M |
| Stockholders' EquityBook value | $1.3M | $123.1M |
| Total Assets | $135.4M | $228.8M |
| Debt / EquityLower = less leverage | — | 0.26× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | $152.4M | ||
| Q3 25 | $10.9M | $184.5M | ||
| Q2 25 | $683.0K | $218.0M | ||
| Q1 25 | $1.6M | $251.7M | ||
| Q4 24 | $2.3M | — | ||
| Q3 24 | $1.6M | $271.1M | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | — | $32.5M | ||
| Q3 25 | — | $32.4M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $32.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $30.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.3M | $123.1M | ||
| Q3 25 | $4.2M | $144.0M | ||
| Q2 25 | $-19.9M | $176.7M | ||
| Q1 25 | $-15.8M | $210.2M | ||
| Q4 24 | $-12.6M | — | ||
| Q3 24 | $-3.8M | $229.1M | ||
| Q2 24 | $-4.7M | — | ||
| Q1 24 | $-745.0K | — |
| Q4 25 | $135.4M | $228.8M | ||
| Q3 25 | $82.6M | $262.2M | ||
| Q2 25 | $59.3M | $298.6M | ||
| Q1 25 | $103.6M | $332.7M | ||
| Q4 24 | $105.5M | — | ||
| Q3 24 | $158.6M | $348.0M | ||
| Q2 24 | $195.2M | — | ||
| Q1 24 | $201.5M | — |
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $-32.0M |
| Free Cash FlowOCF − Capex | — | $-32.2M |
| FCF MarginFCF / Revenue | — | -1253.3% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-139.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | $-32.0M | ||
| Q3 25 | $-4.6M | $-32.5M | ||
| Q2 25 | $-1.2M | $-33.3M | ||
| Q1 25 | $-1.7M | $-37.6M | ||
| Q4 24 | $555.0K | — | ||
| Q3 24 | $-74.0K | $-27.9M | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | — | $-32.2M | ||
| Q3 25 | — | $-33.9M | ||
| Q2 25 | — | $-34.5M | ||
| Q1 25 | — | $-39.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-29.3M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -1253.3% | ||
| Q3 25 | — | -1349.6% | ||
| Q2 25 | — | -1123.1% | ||
| Q1 25 | — | -1801.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -2792.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 56.8% | ||
| Q2 25 | — | 41.6% | ||
| Q1 25 | — | 70.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 130.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.51× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
